View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 7, 2019

Exicure adds new sites to Phase Ib/II trial of AST-008

Exicure has added four new clinical trial sites for its Phase Ib/II trial of AST-008 for the treatment of various cancer types.

Exicure has added four new clinical trial sites for its Phase Ib/II trial of AST-008 for the treatment of various cancer types.

The sites are based in the US, including Dana Farber Cancer Institute in Massachusetts, Holden Comprehensive Cancer Center at the University of Iowa, John Wayne Cancer Institute at Providence St John’s Health Center in California, and Sylvester Comprehensive Cancer Center at the University of Miami in Florida.

Exicure CEO Dr David Giljohann said: “We are encouraged by the results of our Phase I clinical trial, which demonstrated that our drug is well-tolerated and activates key immune cells and signals.

“We are encouraged by the results of our Phase I clinical trial, which demonstrated that our drug is well-tolerated.”

“Eligible patients will be able to enrol in trial sites in the US.”

The initial stage of the open-label Phase Ib/II trial includes a dose-finding Phase Ib stage, where AST-008 is expected to be evaluated in combination with an anti-PD-1 therapy pembrolizumab (Keytruda).

The Phase Ib stage is set to be followed by a Phase II expansion stage.

Exicure aims to enrol patients with superficial injectable tumours as part of the Phase Ib portion of the trial.

Patients will be prioritised as per their cancer types such as Merkel cell carcinoma, cutaneous squamous cell carcinoma, melanoma, and squamous cell carcinoma of the head and neck.

Exicure is scheduled to provide preliminary data from the Phase Ib portion of the trial later this year.

The company is currently developing AST-008 as a toll-like receptor nine (TLR9) activator.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena